Novartis nabs FDA approval for delayed MS drug

Feb 13, 2018

Novartis's Sandoz division has received U.S. approval for a larger dosage of its multiple sclerosis drug Glatopa, which ends a delay that has seen its rival generics sneak past to market.

The U.S. Food and Drug Administration (FDA) approved a 40 milligrams per milliliter injection of the Novartis copy of Teva's blockbuster Copaxone.

In 2015, Sandoz started to sell a 20 mg/ml Glatopa dosage to patients in the United States with relapsing MS. But the company has lost out on possibly millions after the 40 mg/ml version of the treatment was pushed back after contamination issues at the Pfizer fill-and-finish plant it employed.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments